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ABSTRACT
The number of international travellers has increased substantially during recent 
decades. Along with this, the number of travel-related health problems, both during 
and after travel, has also increased. This thesis addresses illness and injury in Finnish 
travellers, with its focus on infections. The main aim was to find tools for risk-
assessment, pre-travel advice, and post-travel examination of travellers.
The specific aims were (1) to provide a comprehensive overview of illness and 
injury of Finnish travellers diagnosed while abroad, and to calculate the incidences 
in various geographic regions and countries, (2) to define the causes of fever in 
returning travellers and to improve clinical differential diagnostics, (3) to identify 
risk groups for imported malaria in Finland, and (4) to analyze in detail the risk 
groups for imported malaria, and to explore whether Plasmodium falciparum 
infection can be contracted despite appropriate chemoprophylaxis.
Study I analyzed data on Finnish travellers with health problems abroad during 
2010–2012, retrieved from the database of an assistance organization of insurance 
companies (SOS International) covering approximately 95% of all Finnish cases 
requiring aid abroad. These data were compared to numbers of Finnish travellers 
retrieved from the database of the Official Statistics of Finland (OSF) in order 
to calculate the incidences of illness and injury at various destinations. The SOS 
database included 50 710 cases: 85% outpatients and 16% inpatients. The most 
common diagnostic category was infections (60%), followed by injuries (14%). The 
most common diagnoses were acute gastroenteritis (23%) and respiratory infections 
(21%). Overall incidence of illness or injury was high in Africa, southern Europe 
plus the eastern Mediterranean, and Asia. Incidence of infections was high in Africa, 
yet it was also high in southern Europe plus the eastern Mediterranean and Asia. 
Incidence of injuries was highest in southern Europe plus the eastern Mediterranean 
and Asia. This study shows that pre-travel counselling is necessary also for travel to 
southern Europe, and that means for prevention of gastrointestinal and respiratory 
infections in travellers need development. 
Study II explored the final diagnoses of returning travellers with fever. The 
study included 462 febrile adults who, after travelling in malaria-endemic areas, 
were admitted during 2005–2009 to the Helsinki University Central Hospital 
emergency room; their medical records were studied retrospectively. The most 
common diagnostic categories were acute diarroheal disease (27%), systemic febrile 
illness (15%), and respiratory illness (15%). One traveller in four had a potentially 
life-threatening illness; septicemia was as common as malaria (5% vs. 4%). One 
in ten had more than one newly-acquired diagnosis. Only 42% of those fulfilling 
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the criteria of influenza-like illness were tested; their nasal swabs for influenza 
A and B antigen were positive in 15%.  The proportion of HIV cases (1% of all 
patients) exceeded its prevalence in the population for which routine HIV testing 
is recommended. These data show the importance of careful diagnostics in cases 
of febrile returning travellers, suggesting that in a tertiary hospital, the diagnostic 
protocol for fever without localizing symptoms in a traveller returning from malaria-
endemic area should – in addition to malaria smears – include blood cultures, an 
influenza rapid diagnostic test, and an HIV test.
Study III analyzed surveillance data on malaria cases reported to the National 
Infectious Disease Register in Finland 1995–2008, and related them to travel 
statistics and antimalarial drug sales. A total of 484 cases were reported (incidence, 
0.7/100 000 population). Infections were mostly acquired in Africa (76%). The most 
common species were Plasmodium falciparum (61%) and P. vivax (22%). During 
2000–2008, travel to malaria-endemic areas increased, yet no increase occurred 
in malaria cases, and a decreasing trend occurred in the number of antimalarial 
drug sales. Of all cases, 283 were Finnish-born and 201 foreign-born. Of all cases, 
15% were children, 72% of them foreign-born. Among those foreign-born, for 
89%, the infection was acquired in the region of birth, implying that immigrants 
visiting friends and relatives (VFR travellers) are a risk group on which effort in 
disseminating pre-travel advice should focus. 
Study IV analyzed in detail the background information of all malaria cases 
diagnosed in Finland 2003–2011, a total of 265 cases (incidence 0.5/100,000 
population): 54% were born in malaria-endemic countries, 86% were currently 
living in non-endemic regions. Malaria was most commonly contracted in sub-
Saharan Africa (81%). Plasmodium falciparum proved to be the most common 
species (72%). Immigrants constituted the largest group (44%). Of those born in 
endemic regions, 20% had received pre-travel advice, compared with 81% of those 
born in non-endemic regions. Of those with P. falciparum, 4% reported regular 
use of appropriate chemoprophylaxis; individual rechecking revealed, however, 
that none had been fully compliant. The data suggest that mefloquine, atovaquone/
proguanil, and doxycycline are effective as chemoprophylaxis against P. falciparum 
malaria, when taken conscientiously.
12
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1 INTRODUCTION
We no longer live isolated from other countries: we travel because of leisure, work, 
education, and migration. International travel has, in recent decades, increased 
substantially: the annual number of international tourist arrivals worldwide reached 
1 000 million in 2012, and by 2030 is expected to reach 1 800 million. Travel to 
emerging economies in Asia and the Pacific, followed by Africa, is expected to 
increase at double the pace of travel to advanced economies,1 with the need for 
health care during travel expected to increase accordingly. Over half the travellers 
to developing countries are estimated to fall ill during their trip,2 and 8% to require 
medical attention.2,3 Few data have been published on travel to developed countries. 
The escalating numbers of travellers cause a rising burden on health care systems 
both in the host countries during travel and in the countries of origin after their 
return. Infectious diseases do not recognize borders: with travellers, epidemics may 
spread from one country to another. Increasing international travel is also reflected 
as rising numbers of imported infectious diseases in Europe, among them, severe, 
life-threatening diseases.4,5 
Travel medicine is a relatively newly established medical specialty which covers 
a broad spectrum of issues: epidemiology of travel-related health problems, risk-
assessment, and pre-travel advice, as well as post-travel diagnostics and treatment. 
Travel medicine overlaps tropical medicine, infectious diseases, general medicine, 
public health, epidemiology, migration medicine, and global health. Many studies 
have recorded health problems of travellers after their return diagnosed in specialized 
travel medicine clinics or referral centres, whereas only limited data has been focused 
on illness and injury diagnosed during travel abroad. 
Among international travellers, Europeans represent the largest group.1 Finland 
is among the few countries that monitor the annual numbers of their travellers to 
various destinations. The number of international travellers has more than doubled 
during the last decade, and Finns, with a population of 5.4 million inhabitants, 
made 7.7 million at-least-overnight trips abroad in 2012,6 the majority of them to 
nearby regions, but considerable numbers also to tropical and sub-tropical regions.
This thesis addresses the illness and injury of Finnish travellers, with a focus on 
infections. It aims at a comprehensive overview of illness and injury of travellers 
diagnosed while abroad, and an estimation of health risks in various geographic 
regions during travel. It also focuses on life-threatening infections after travel by 
exploration of causes of fever in returning travellers, and by analysis of all malaria 
cases diagnosed in Finland 1995–2011. 
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2 REVIEW OF THE LITERATURE 
2.1. ILLNESS AND INJURY OF TRAVELLERS 
Along with expansion of international travel, data on the illness and injury of 
travellers has become increasingly important.7,8 Reporting and surveillance of 
travel-related illnesses is of public-health importance. An epidemic may spread 
across international borders along with travellers,7–10 returned travellers may serve 
as sentinels of an outbreak or epidemic,11 and recognition of disease may lead to 
measures to limit the transmission in the country of the travel.12–14 Epidemiological 
data on travellers’ health problems constitute an evidence-base for health 
recommendations to travellers.3,15 Such data are necessary for risk-assessment 
when prioritizing preventive measures for an individual traveller in pre-travel 
counselling,16–18 and benefit clinicians who must consider possible differential 
diagnoses after travel.19,20 
2.1.1. ESTIMATING HEALTH RISKS RELATED TO TRAVEL
Several research approaches have been used for estimating risk for illness or injury 
during travel: case reports, case series,21–23, chart reviews24–27 case-control studies,28–32 
cross-sectional studies often performed as airport surveys,33–46 prospective cohort 
studies,2,3,47–56 use of notification data,57–62 and sentinel-surveillance data.4,12,63–75 The 
classification of diseases used in the studies varies, making comparisons difficult. 
Leder et al have made a comparative analysis of the methodological approaches 
used19 and concluded that each approach has its strengths, limitations, and biases, 
which considerably affect the risk estimates and generalizability of the results. 
Steffen3,15,76,77 has presented calculations of the estimated incidence of travellers’ 
health problems in developing countries per month abroad; these figures have 
served as the basis for many risk estimates in travel medicine.19 GeoSentinel, a 
multicentre surveillance network reporting mainly post-travel health problems, uses 
proportionate morbidity: the number of travellers with a given diagnosis divided by 
the total number of ill travellers.19,68,74,78 The main limitation in all these studies is the 
lack of numbers of those travelling to the destinations,19 which may cause distortion 
in the proportions of health problems. Travel statistics have served as denominator 
data to estimate the incidence of single imported diseases.60,61,79,80 Data providing 
comprehensive numerator and denominator data for calculation of incidence of the 
whole spectrum of travellers’ health problems are, however, lacking.19
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2.1.2. ILLNESS AND INJURY DURING TRAVEL 
ILLNESS DURING TRAVEL
Cross-sectional and prospective studies
Cross-sectional and prospective studies have shown that 12 to 70% of travellers, 
depending on destinations and the traveller population, encounter health problems 
during travel2,3,33–37,47,49–53,81,82 (Table 1). Various studies report 3 to 11% of travellers 
as seeking medical care,2,3,33,34,37,47,49,50,52,53,81 and 0.1 to 0.5% to be hospitalized while 
abroad.2,3,50,52,53 A study on Israeli travellers51 has reported an exceptionally high 
proportion (70%) of travellers with health problems; 33% sought medical care and 
4% needed hospital treatment during travel. The authors attributed these findings 
to the demographic profile of their travellers. They were younger and travelled for 
longer periods of time and in more primitive settings than did those in the other 
studies. 
Risk factors for illness during travel
Young age3,37,47,49,52,53 and long duration of travel2,3,33,49,51–53 have both been reported 
as risk factors for illness during travel. Among studies, the overall frequency of 
health problems and that of specific symptoms has varied according to travel 
destination and geographic area visited.2,3,33–37,49,52,53,82 Most of the studies have been 
done on those travelling from developed to developing countries.2,3,36,47,51,52 Health 
problems associated with travel to or within Europe have been studied less4,34,53,82; 
rates of illness have shown regional differences, with the highest rates in travellers 
to the Mediterranean countries34,82 or eastern Europe.4,82 Other factors reported 
as associated with increased risk for health problems abroad include reason for 
travel,3,33,34 living among the local population,3 adventure tourism,3,49 travelling 
under primitive conditions,52 poor travel preparation,82 inexperience in travel,37 
poor compliance with food hygiene,51 travel  with friends rather than family,51 travel 
alone,51 female gender,2 and various pre-existing medical conditions.53  
Types of illness during travel
All studies have reported diarrhoea as the most frequent health problem (11–59%) 
encountered during travel.2,3,33–37,47,49–53,81,82 Respiratory infections rank second 
(2–26%).2,3,33–37,49–53,81 Skin problems2,3,35,47,52,82 and fever2,3,47,50,52 are among the next 
most commonly reported. 
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Consequences of illness during travel
Illness during travel has been reported to cause incapacitation or confinement to 
bed in 14 to 24% of travellers37,49,50 for a mean of 2–3 days.49,50 In one Swedish 
study, the mean duration of illness was 4.5 days49; one Swiss study has calculated 
incapacitation to cause a loss of 2% of total time abroad.50 A Norwegian study has 
reported 11% to have changed plans because of illness with a mean of 3.5 travel days 
lost, and 8% to have felt  that illness made their travel less enjoyable.47 A German 
study has showed, however, that the positive effects of travel outweighed the health 
problems, and travel had a positive effect on subjectively perceived health status.53 
Prospective studies based on post-travel questionnaires and interviews do not record 
deaths that have occurred during travel.
Studies based on travel insurance claims and data from assistance organizations
In contrast to reports described above, studies based on travel insurance claims 
(Table 2a) have reported respiratory diseases to be the most common category 
of illness.83,84 In one Polish study, 75% of the claims were because of illness, 25% 
because of injury.83 
Although acquired for other purposes, data of emergency assistance organizations 
have been suggested as potentially valuable sources of information on events taking 
place during the actual travel.85 Three studies are based on data of emergency 
assistance services of single major insurance companies in Switzerland, Australia, 
and Norway85–87 (Table 2b). Assistance had been necessary because of illness in 
69 to 76% of cases, and because of injury in 24 to 31% of cases.85,87 These studies 
show nearly equal proportions of genders; 22 to 32% of their travellers with health 
problems were over age 60. In the Norwegian study, the proportion of cases with 
illness increased with age, whereas most injuries had occurred in those in the age 
group 15 to 29 years.87 Traumas had accounted for 24 to 31% of the cases in these 
studies, with most of the fractures in the extremities.85,87 The illness-to-accident 
ratio was higher in developing than in developed countries, mostly attributed to 
infectious and gastrointestinal illness.85,87 Infections were the most common illnesses 
in the Norwegian87 and Swiss85 studies (20% vs. 26%), musculoskeletal symptoms 
(28%) in the Australian86 report. Rate of hospitalization was higher than in the 
prospective studies, ranging from 12%86 to 46%,87 which suggests that these cases 
represent more serious health problems than did those in prospective studies.87 
Aeromedical evacuation was needed in 2.3 to 2.5%,86,87 the proportion of deaths 
ranged from 0.2%86 to 3.7%.87 
19
Ta
bl
e 
2 
St
ud
ie
s 
on
 h
ea
lth
 p
ro
bl
em
s 
ab
ro
ad
 b
as
ed
 o
n 
in
su
ra
nc
e 
cl
ai
m
s 
an
d 
da
ta
 o
f 
as
si
st
an
ce
 o
rg
an
iz
at
io
ns
Fi
rs
t a
ut
ho
r, 
co
un
tr
y,
 
pu
bl
ic
at
io
n 
ye
ar
N
G
en
de
r, 
m
al
e,
 
%
A
ge
  
>6
0
 y
,  
%
Ill
ne
ss
, 
%
In
ju
ry
, 
%
H
os
pi
ta
liz
ed
, 
%
Re
pa
tr
ia
te
d 
by
 
ai
r 
am
bu
la
nc
e,
 
%
D
ea
th
, 
%
D
ia
gn
os
tic
 c
at
eg
or
ie
s 
of
 il
ln
es
se
sa
2a
 S
tu
di
es
 b
as
ed
 o
n 
tr
av
el
 in
su
ra
nc
e 
cl
ai
m
s 
of
 s
in
gl
e 
m
aj
or
 in
su
ra
nc
e 
co
m
pa
ni
es
To
m
az
un
as
,83
 
Po
la
nd
,  
20
0
0
3 
20
0
 
N
A
N
A
75
 
25
 
N
A
N
A
1.0
of
 a
ll 
ca
se
s:
 
22
%
 r
es
pi
ra
to
ry
, 1
1%
 g
as
tr
oi
nt
es
tin
al
 (
in
cl
ud
in
g 
di
ar
rh
oe
a)
, 9
%
 c
irc
ul
at
or
y,
 5
%
 e
ar
, 
5%
 g
en
ito
ur
in
ar
y,
 2
%
 in
fe
ct
io
us
 d
is
ea
se
s
Le
gg
at
,84
 
A
us
tr
al
ia
,  
20
0
2
56
9
N
A
N
A
10
0
N
A
N
A
N
A
0.
4
of
 a
ll 
ca
se
s:
 
20
%
 r
es
pi
ra
to
ry
, 1
7%
 m
us
cu
lo
sk
el
et
al
,  
14
%
 g
as
tr
oi
nt
es
tin
al
, 1
3%
 e
ar
, n
os
e,
 a
nd
 t
hr
oa
t, 
 
7%
 d
en
ta
l, 
7%
 v
as
cu
la
r, 
5%
 d
er
m
at
ol
og
ic
al
,  
5%
 g
en
ito
ur
in
ar
y
2b
 S
tu
di
es
 b
as
ed
 o
n 
da
ta
 o
f e
m
er
ge
nc
y 
as
si
st
an
ce
 s
er
vi
ce
s 
of
 s
in
gl
e 
m
aj
or
 in
su
ra
nc
e 
co
m
pa
ni
es
So
m
er
,85
 
Sw
iz
er
la
nd
, 
20
0
3
24
2
52
28
 
69
31
N
A
N
A
N
A
of
 a
ll 
ca
se
s:
 
26
%
 in
fe
ct
io
ns
, 8
%
 c
ar
di
ov
as
cu
la
r, 
7%
 g
as
tr
oi
nt
es
tin
al
 (
in
cl
ud
in
g 
di
ar
rh
oe
a)
Le
gg
at
,86
 
A
us
tr
al
ia
,  
20
0
5 
40
0
46
 
22
N
A
N
A
12
2.
5
0.
2
of
 il
ln
es
se
s:
28
%
 m
us
cu
lo
sk
el
et
al
, 1
5%
 g
as
tr
oi
nt
es
tin
al
,  
14
%
 d
en
ta
l, 
12
%
 r
es
pi
ra
to
ry
, 
8%
 e
ar
, n
os
e,
 a
nd
 t
hr
oa
t, 
6%
 d
er
m
at
ol
og
ic
al
,  
4%
 g
en
ito
ur
in
ar
y,
 3
%
 c
ar
di
ov
as
cu
la
r, 
3%
 o
bs
te
tr
ic
Le
rd
al
,87
 
N
or
w
ay
,  
20
07
1 
78
7
55
 
32
 
76
24
46
2.
4
3.
7
of
 il
ln
es
se
s:
20
%
 in
fe
ct
io
ns
 (
in
cl
ud
in
g 
tr
av
el
le
r’s
 d
ia
rr
ho
ea
 
an
d 
pu
lm
on
ar
y 
in
fe
ct
io
ns
),
 1
0
%
 p
ul
m
on
ar
y
a c
om
pa
ris
on
s 
be
tw
ee
n 
st
ud
ie
s 
no
t 
fu
lly
 r
el
ia
bl
e,
 s
in
ce
 t
he
 d
ia
gn
os
tic
 c
at
eg
or
ie
s 
w
er
e 
no
t 
un
ifo
rm
20
REVIEW OF THE LITERATURE
INJURY DURING TRAVEL
Accidents or injuries have been reported by 0.5 to 7% of travellers in the prospective 
cohort studies.2,3,49–53 Studies based on travel insurance claims or data of assistance 
organizations have reported these in 24 to 31%.83,85,87 McInnes88 reviewed 25 studies 
on injury during foreign travel. Several of the studies reported injury deaths to be 
more common among tourists than among local residents, and young men as the 
most likely victims of trauma.88 Injury, defined as “an event that has an external 
cause and is potentially preventable,” has proved one of the main causes of death 
during travel (18–35%).88 Pre-travel advice should thus include advice on traffic, 
safety, and prevention of injuries.89
DEATH DURING TRAVEL 
While infections are frequent among travellers, they only rarely cause serious or 
long-term consequences and have been reported as rare causes of death during 
travel.76,90–92 Cardiovascular diseases and injuries are much less frequent, yet 
account for the majority  travel-related deaths.76,90–92 In most studies, age-specific 
cardiovascular mortality has not been higher in travellers than in the non-travelling 
population, whereas accidents have been the leading cause of excess mortality, 
especially among the young76,90,92,93 and male91.  Lunetta’s92 analysis of the causes 
of death of Finnish travellers abroad during 1969–2007 showed cardiovascular 
diseases to be the most common cause (44%), yet injury-death rates were more 
than three times as high as in Finland and represented 27% of all deaths abroad, 
with a peak among 20– to 30-year-olds. As in other reports,88 the most common 
causes  of unintentional injury deaths were traffic accidents (45%) and drowning 
(16%), followed by falls and poisoning; infections caused only 1.3% of deaths.92 
2.1.3. FACTORS INFLUENCING THE RISK OF HEALTH PROBLEMS  
RELATED TO TRAVEL
FACTORS ASSOCIATED WITH THE TRIP
Destination 
Studies have shown significant differences in travellers’ morbidity between 
geographical regions. The study of GeoSentinel,68 comprising 17 353 travellers 
returning ill from 1996 to 2004, has reported systemic febrile illness more frequently 
among those returning from sub-Saharan Africa or southeast Asia, acute diarrhoea 
more from south-central Asia, and skin problems more from the Caribbean or 
21
Central or South America. Malaria has been one of the three most frequent causes 
of systemic febrile illness in every region, and the most common cause of fever in 
travellers to sub-Saharan Africa.68 Other studies have shown rather similar results, 
findings depending on destinations.2–4,27,33–37,49,52,53,70,74,82,94 A sentinel-surveillance 
study on European travellers returning ill4 has reported travel within Europe also 
to be associated with health risks: 17% had a gastro-intestinal illness, 14% had a 
respiratory illness, and 8% had some dermatological condition. Disease patterns of 
eastern and western Europe differed; cases with gastroenteritis, potentially vaccine-
preventable diseases, acute sexually transmitted diseases (STD), and tuberculosis 
were diagnosed more frequently among those visiting eastern than western Europe.4
Duration of travel
The longer a trip’s duration, the higher the risk for developing illness.2,3,34,49,51–53 
In a study exploring journeys lasting less than three months, Hill has found the 
chance of becoming ill to increase by 3 to 4% with each travel day.2 Long-term 
travellers and expatriates who reside abroad for years differ from other travellers 
with respect to exposures and risks. A GeoSentinel analysis has showed malaria, 
prolonged gastrointestinal symptoms and protozoal infections, eosinophilia, 
cutaneous leishmaniasis, schistosomiasis, and prolonged fatigue to be more frequent 
among long-term than short-term travellers.95 An analysis of returning travellers 
has showed latent tuberculosis more frequently among expatriates than others; 
volunteer-worker expatriates presented more frequently with parasitic infections, 
business  expatriates with vector-borne and vaccine-preventable infections.96 
FACTORS ASSOCIATED WITH THE TRAVELLER
Sex and gender issues
A GeoSentinel study97 has shown women to obtain pre-travel advice more than men 
do, and to have after travel more frequently all types of diarrhoea, upper respiratory 
and urinary tract infections, psychological stressors, oral and dental conditions, 
and adverse reactions to medications. Men have been shown more likely to have 
febrile and vector-borne diseases such as malaria, leishmaniasis, and rickettsioses; 
sexually transmitted diseases; viral hepatitis; and non-infectious problems including 
cardiovascular disease. The authors concluded that some of the differences may be 
related to individuals’ sex and some to gender-related behaviour.97 Ill women have 
been less likely to be hospitalized on their return than men.27,97 Studies on febrile 
hospitalized travellers after travel have also shown a male predominance.26,94,98–102 
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Age
Children
Studies on children, similar to those on adults, have shown an association between 
morbidity and geographical area visited,56,103–105 and diarrhoea to be the most 
common post-travel health problem.103–105 Traveller’s diarrhoea has been more 
severe in children under 12 than in older age groups, and some studies have shown 
the highest rates among children aged <2 years.48,54,55 
One Swiss study54 has showed no difference in morbidity during travel between 
children and their adult relatives, with the exception of fever as being more frequent 
in children. By contrast, a Dutch study56 has showed those in the age-group 12 to 18 
years with higher morbidity than their parents; as a cause, the authors suggested 
that children of this age are no longer under the strict supervision of their parents, 
and may take health risks. Their most common health problems were mild skin 
problems and abdominal complaints.
Post-travel data of GeoSentinel103 has showed in children a higher proportionate 
morbidity from gastroenteritis, respiratory disorders, and dermatological syndromes 
than in adults. Children have been more likely than adults to be visiting friends 
and relatives (VFR), not to have received pre-travel counselling, and to require 
hospitalization after travel. Their most common diagnoses have been diarrhoea 
(25%), systemic febrile illness (23%), and respiratory disorders (11%); the most 
common systemic febrile illness has been malaria (35%). No deaths occurred.103 A 
post-travel study in one German university hospital104 has showed 50% of patients in 
age group 0 to 4 years to be VFR. Another study in a similar setting in Switzerland105 
has reported a potentially serious illness in 4% of ill paediatric travellers, nearly all 
of them VFR. Children visiting friends and relatives are thus considered a vulnerable 
risk group of travellers.106 
Young adults
The rate of health problems is reportedly higher among young than older 
travellers.3,37,47,49,52,53,107–109 Young  adult travellers have also been described to 
experience subjectively health problems more often than those older, probably 
because of lack of experience in travel and in being ill.47 Young adults, especially 
young men, are more prone to injury and accident-related death than are other 
travellers.88
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The elderly 
A prospective study on travellers over age 60110 showed them to comply with health 
recommendations more frequently than do those aged 20 to 30. Traveller’s diarrhoea 
proved less common in the older age group (19% vs. 34%),110 as shown also in other 
studies.109 This finding may in part be explained by those older being more cautious 
and partly by intestinal immunity developing with repeated lifetime exposures.109 
A sentinel study comparing those over 60 to 18- to 45-year-olds111 showed lower 
proportional morbidity in the older age group from acute diarrhoea and upper-
respiratory-tract infections, malaria, and dengue; and higher morbidity from 
arthropod bites, rickettsiosis, severe malaria, lower-respiratory-tract infections, 
urinary tract infections, diseases of the upper gastrointestinal tract, phlebitis, 
pulmonary embolism, heart disease, trauma, and injury; the older age group had 
a higher death-rate.111 
PURPOSE OF TRAVEL
VFR travellers
A traveller visiting friends and relatives (VFR) has recently been re-defined as 
“a person whose primary purpose of travel is to visit friends or relatives and for 
whom there is a gradient of epidemiologic risk between home and destination, 
regardless of race, ethnicity, or administrative/legal status.”112 VFRs represent a 
distinct group of travellers at increased risk for travel-related health problems.113 
They stay in close contact with the local population, the trip often lasts longer, and 
they are more exposed to health risks than are other travellers.114 VFR travellers less 
often seek pre-travel advice,41,114,115 and are more likely than other travellers to be 
hospitalized and have serious illnesses after travel.114,115 They have been   more likely 
than other travellers to be diagnosed with malaria,70,74,79,100–102,114,116 typhoid fever,115 
other systemic febrile illnesses,115 respiratory infections,115 influenza,117 tuberculosis,115 
viral hepatitis,114 HIV-infection,114 sexually transmitted infections,114 and intestinal 
parasitic infections;115 yet less often with acute diarrhoea114,115 or dermatologic 
conditions.115 Malaria cases of VFR travellers have been mostly reported among 
those visiting sub-Saharan Africa.70,74,100,101,114 
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Occupational travellers 
Studies on occupational travellers have shown higher rates of illness and injury and 
a higher frequency of psychological problems than in other types of travellers,118 
with the most common disease reported as being diarrhoea.118,119 In a study on 
insurance claims of World Bank employees,120 rates of infectious and intestinal 
diseases and diseases of the skin and subcutaneous tissue increased with number 
of international missions; the greatest excess morbidity related to travel was in 
psychological disorders.
2.1.4. TRAVELLERS’ MOST COMMON DISEASES
GASTROINTESTINAL INFECTIONS
Traveller’s diarrhoea
The most common travel-associated disease is traveller’s diarrhoea (TD), affecting 
20 to 60% of those travelling from developed to developing countries107,121,122 and 
estimated to affect annually at least 11 million individuals.123 TD is defined by World 
Health Organization (WHO) criteria124 as the passage of three or more loose or liquid 
stools per day, or more frequently than is normal for the individual. TD incidence 
depends on travel- and traveller-related risk factors.109 
Travel-related risk factors of TD
The most important travel-related risk factor is destination. Three risk areas have 
been defined according to TD incidence during a 2-week stay: low-risk areas with 
an incidence of 8% or less as including central and northern Europe, the USA, 
Canada, Australia, and New Zealand; intermediate-risk areas with an incidence of 
8 to 20% comprising southern and eastern Europe, Russia, Japan, the Caribbean, 
Chile, Argentina, and South Africa; high-risk areas with an incidence of 20 to 90% 
including the Middle East, Asia, Central and South America, and Africa.107 Risk 
varies between regions, countries, and even hotels.38,39,107 A review by Steffen in 
2005107  showed  a reduction in TD  rates  during recent decades in southern Europe, 
but not in other destinations. The second most often recognized travel-related factor 
is trip duration; risk is highest during the first week125 and declines with  duration of 
stay, probably because of acquired immunity to enteropathogens.21 The third factor 
is type of travel: the risk increases the more adventurous the trip.126
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Traveller-related risk factors of TD
Travellers from countries with high sanitary standards have been shown to have higher 
TD rates than do travellers from less developed countries, suggesting lack of  acquired 
intestinal immunity.125,127 The risk for TD has appeared highest in infants, toddlers, 
and young adults,21,39,48 and to be unrelated to gender.39,109 Recognized predisposing 
risk factors for gastrointestinal infections include genetic susceptibility,107,121,123,128 
medications reducing gastric acidity,129,130 and immunosuppression.131
Aetiology and clinical picture of TD
Bacteria and their toxins have been reported to cause as many as 75% of the TD 
cases.132,133 The causative micro-organism has remained unidentified in up to half 
the cases,132–135 but new diagnostic methods may improve  diagnostic accuracy.136–139 
The usual incubation period is 4 to 7 days, 90% of cases presenting during the first 
2 weeks of the stay.109 Half of such travellers are incapacitated for at least one day, 
20% are confined to bed for 1 to 2 days. Medical consultation is needed in 5 to 15%, 
but need for hospitalization is rare. TD is usually self-limiting by 5 days without 
treatment, but may result in complications in those with underlying morbidity. 
Antimicrobials can shorten the illness by 1 to 2 days.109 The effect of food hygienic 
measures in the prevention of TD has proved to be limited.39,140,141
Gastrointestinal symptoms after travel
Studies of the GeoSentinel network on travellers returning ill have showed the 
highest risk for post-travel gastrointestinal problems to occur after journeys to 
South Asia, followed by sub-Saharan Africa and South America,80 and post-travel 
symptoms to be more common in women.97,108  
RESPIRATORY INFECTIONS 
Acute respiratory infections have occurred in 2 to 26% of travellers during2,3,33–37,49–53,81 
and in 8 to 11% following travel.4,68,70,74 In the prospective study of Hill,2 respiratory 
tract symptoms were reported by 26% during and by 10% following travel.
In a GeoSentinel study on returned travellers,117 8% of all infections were  of 
the respiratory tract, among which, the most common diagnosis were nonspecific 
upper respiratory infection (47%), followed by pharyngitis (13%). Lower-respiratory-
tract infections accounted for 40%: bronchitis for 20%, pneumonia for 14%, and 
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influenza for 6%. Lower-respiratory-tract infections have been associated with male 
gender and increasing age, with risk for upper-respiratory-tract infection greater 
in younger persons. Influenza has been associated with travel visiting friends and 
relatives and trips of long duration, but not with traveller’s age.117 
Mutsch and colleagues142 have demonstrated seroconversion of influenza-specific 
antibodies in 2.8% of 1 450 travellers and calculated an incidence of 1.0 influenza-
associated events per 1 000 person-months abroad, suggesting influenza as the 
most frequent vaccine-preventable infection of travellers to subtropical and tropical 
countries. During the A(H1N1) influenza pandemic in 2009, other influenza viruses 
and rhinovirus were also frequent causes of respiratory infection in travellers.143
2.1.5. ILLNESS AFTER TRAVEL 
Few studies exist on overall travel-related illness or mortality after travel, and none 
on long-term morbidity. 
Prospective studies on health problems during travel have followed travellers for 
up to 7 months; 25 to  33% of these travellers have been ill on or after return,2,3,47 9 to 
46% have consulted a physician,2,47,50,51 and 0.1 to 1% have been hospitalized.47,50 In 
one  Norwegian study,47 25% had health problems after the trip, 9% had consulted a 
doctor, and 1% had been hospitalized; 50% had suffered gastrointestinal problems, 
25% upper-respiratory infections, 18% had experienced general ill health, and 8% 
skin problems. In the Hill study,2 46% of ill travellers sought medical care after 
travel, compared to 12% during travel; the most common post-travel problems 
were gastrointestinal symptoms (31%), followed by respiratory tract illness (24%), 
febrile episodes (13%), and skin problems (11%). 
A US study examining causes of travel-related deaths after return has found 
most to be cardiovascular (70%).144 The proportion of infections was found higher 
than in studies on death during travel91,92 (12% vs. 1.3–3%). Pneumonia was the 
most common infectious cause of death (53%); 73% of these patients had some 
underlying chronic condition.144
INFECTIONS IN RETURNED TRAVELLERS 
Most studies on epidemiology of illness in returned travellers are based on data 
from either a single referral centre24,25,27,94,100,114,145 or from a surveillance network of 
centres for tropical and travel medicine,4,68,70,74 and they mainly describe infections 
(Table 3). 
27
Studies based on hospital data have reported fever as the most common 
presenting symptom (43–77%).27,100,114,145 Of the final diagnoses, gastrointestinal 
diseases have represented 9 to 49%, respiratory diseases 3 to 12%, and skin diseases 
5 to 8%.24,25,27,94,100,114,145 Malaria has been the most common single diagnosis in 
hospitalized patients (9–49%).24,25,27,94,100,145 In studies reporting mortality data, the 
figures have proved to be low (0.2–0.6%).94,114
In studies based on data of surveillance centres,4,68,70,74 including mainly 
outpatients, the most common diagnostic categories have been gastrointestinal 
infections (33–42%), systemic febrile illnesses without localizing symptoms (20–
23%), and skin diseases (12–20%). Malaria has been the most common single 
diagnosis, followed by dengue. Malaria diagnoses have been proportionately most 
frequent in those returning from Africa.
FEVER IN RETURNED TRAVELLERS 
Several studies have presented fever as one of the most common reasons (28–77%) 
for seeking medical help after travel.27,100,114,145,147 When examining travellers with fever 
without focal symptoms, the clinician faces a multitude of diagnostic alternatives.148 
The most important task is to recognize the treatable potentially life-threatening 
diseases148,149 and the few infections highly transmissible from person to person 
requiring special infection-control measures.148 When examining a febrile returned 
traveller, it is essential to take a chronological history covering travel itinerary and 
course of illness. This information, combined with knowledge of infection-specific 
incubation periods, allows the clinician to exclude diagnoses which are, time-wise, 
unlikely and to focus on the more likely diagnoses.148 
Data on fever in returned travellers have been based on studies conducted in 
tertiary hospitals or referral centres for travel or tropical medicine.26,27,94,98–102,147 
Outpatients were included in one single-centre study101 (73%) and one multicentre 
study147 (74%); other papers have described inpatients only. Thus they all represent 
selected patient material. Median age of the patients has been 30 to 38 years, the 
majority of them (59–71%) male. The proportion of VFR travellers has ranged 
from 0 to 59%, which may affect the findings of individual studies. The region most 
commonly visited has been sub-Saharan Africa (34–86%), except for the Australian 
studies,26,94 in which the most common location has been Asia and the Pacific. The 
results of these studies are presented in Table 4 and discussed below.
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Causes of fever in returned travellers
Malaria has been reported as the most common single reason for travel-related 
fever without local findings (21–75%),26,27,94,98–102,147 and the most common tropical 
disease causing death.101,147 Two of the studies have reported tropical diseases to 
account for 36%100 and 39%101 of the febrile diseases. In addition to tropical diseases 
are worldwide infections.26,94,98,100,101,147 Six studies have reported newly diagnosed 
HIV infections in 0.3 to 1.5% of patients, yet not all febrile returned travellers were 
tested for HIV.26,98–102 In a minority of cases (0–5%), the cause of fever has been 
non-infectious.26,99,101,102 Three studies have reported 10 to16% of patients as with 
more than one diagnosis.98,99,101 Reported mortality has been 0.2 to 0.5%.94,101,147 
The proportion of those remaining without a confirmed diagnosis has ranged 
in various studies from 5 to 24%.26,27,94,100–102,147 In febrile returned travellers whose 
diagnosis had remained unknown in routine investigations, a Swedish study, 
using paired sera, established a diagnosis in 21%. The most common diagnosis 
revealed was influenza (10%), followed by rickettsial infection (5%), dengue (3%), 
leptospirosis (2%), and Q-fever (1%).150 Influenza has been diagnosed as the cause 
of fever after travel in 0 to 5% in other studies.26,94,98,99,102,147 These data suggest that 
influenza in travellers is underdiagnosed.150
A GeoSentinel study has showed patients with fever to be hospitalized more 
often than are those without fever (26% vs. 3%)68; of the febrile patients, 35% 
have been diagnosed with a febrile systemic illness, 15% with febrile diarrhoeal 
disease, and 14% with respiratory infection.147 After malaria, the most common single 
systemic febrile illnesses in the GeoSentinel study have been dengue, enteric fever, 
and rickettsioses.147 In the Belgian study,101 the most frequently diagnosed tropical 
infections after malaria have been rickettsial infections and dengue. 
Travel destination and cause of fever
Fever aetiology depends on travel destination. P. falciparum malaria has been 
the most common cause of fever in travellers returning from sub-Saharan 
Africa,26,27,68,94,99–102,147 whereas dengue, malaria, and enteric fever have been 
among the three most common causes in travellers to Asia,68,101 and dengue the 
most frequent cause in those visiting the Americas.68,101 Rickettsiosis68,101 and acute 
schistosomiasis101 have affected almost exclusively travellers to sub-Saharan Africa.
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Purpose of travel and cause of fever
VFR travellers have represented 8 to 59% of ill febrile returned travellers.27,99–102,147 
In most studies, the majority of diagnosed malaria cases have been in VFRs, most 
of them Plasmodium falciparum infections among those visiting sub-Saharan 
Africa.100–102,147 
Factors predictive for malaria in febrile returned travellers
Several studies have sought factors predicting malaria as the cause of travel-
related fever. Features associated with malaria have been fever without localizing 
symptoms,151 enlarged spleen,151 thrombocytopenia,151–153 leukocytopenia,153 elevated 
lactate dehydrogenase,153 and hyperbilirubinemia.151,153 No clinical or biological 
parameter has proved, however, to have both good specificity and sensitivity to 
differentiate malaria from other diseases.146,154 
In conclusion, malaria should be suspected in all febrile travellers returning from 
malaria-endemic areas and should be excluded by laboratory tests.146,154
2.2. MALARIA
2.2.1. GLOBAL EPIDEMIOLOGY OF MALARIA
Nearly half the world’s population is at risk for malaria. In 2013, malaria was endemic 
in 104 countries or territories in tropical and temperate regions.155,156 The WHO 
estimated that over 200 million cases and 627 000 malaria-related deaths occurred 
globally in 2012155; mortality may, however, be underestimated.157 Most cases (80%) 
and most deaths (90%) occurred in sub-Saharan Africa, and most deaths (77%) 
were in children under age 5.155
Malaria is caused by protozoan parasites of the genus Plasmodium. Five species 
can infect humans: P. falciparum, P. vivax, P. ovale, P. malariae, and the zoonotic 
species P. knowlesi. Of these, P. falciparum is the most common; it predominates in 
Africa and causes most of the malaria-related deaths. P. vivax is more widespread, 
but less serious; the other species are found much less frequently.155 P. vivax is widely 
distributed, because it is able to develop in the mosquito vector at lower temperatures 
and to survive at higher altitudes and in cooler climates than P. falciparum can. It 
also has a dormant liver stage (hypnozoite) enabling it to survive during periods 
when no mosquitoes are present. Many African populations have a high frequency 
of Duffy negativity, which makes red blood cells resistant to P. vivax infection; this 
species is more rare in Africa than in other areas.155
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Transmission intensity depends on factors related to the parasite, the vector, 
the human host, and the environment. Malaria is transmitted through the bites 
of Anopheles mosquitoes, which breed in water. Only about 30 of the more than 
400 Anopheles species are effective vectors, these all bite at night. The African 
vector species has a long lifespan and prefers to bite humans rather than animals, 
the main reasons why transmission in Africa is high.155 In most of Asia and South 
and Central America, transmission is mainly low and seasonal, and prevalences of 
P. falciparum and P. vivax malaria are approximately equal. In these areas, most 
people receive one or fewer infectious bites per year, whereas in most of sub-Saharan 
Africa, where P. falciparum predominates, and in parts of Oceania, transmission 
intensities in some areas are as high as 1 000 bites per year.158
Since 2000, malaria control programmes have led to a reduction in malaria 
incidence and mortality. Between 2000 and 2012, estimated malaria mortality rates 
fell worldwide by 45% in all age groups, and by 51% in children under 5. Malaria 
continues, however, to be a major public-health problem in endemic areas, especially 
in sub-Saharan Africa.155
2.2.2. TRANSMISSION, PATHOGENESIS, AND CLINICAL PICTURE OF MALARIA
Human malaria infection is transmitted from person to person by the bite of 
an infected female Anopheles mosquito; transmission is also possible via blood 
and by congenital transmission. Within a few minutes, through the bloodstream, 
Plasmodium sporozoites enter the liver, where they invade hepatocytes and 
multiply asexually into tissue schizonts. P. vivax and P. ovale may remain in the 
liver as dormant hypnozoites for several months, even years, before proceeding to 
their next stage. In P. falciparum infection, the liver schitzonts rupture after 1 to 
2 weeks, in other Plasmodium species after a longer period. Rupturing schitzonts 
release into the bloodstream merozoites, which invade red blood cells of various 
ages (erythrocytic stage). Within red blood cells, the merozoites mature successively 
from ring forms to trophozoites and further to mature red cell schizonts over a 
period of 24 hours (P. knowlesi), 48 hours (P. vivax, P. ovale, P. falciparum), or 
72 hours (P. malariae). Clinical symptoms appear when the blood cells rupture, 
releasing new daughter merozoites and pro-inflammatory cytokines. Most released 
merozoites continue the asexual circle, infecting new red cells; a few differentiate 
into male or female gametocytes (sexual forms) which may be ingested by a 
mosquito along with a blood meal. The sexual cycle, formation of new sporozoites, 
takes place in the mosquito, completing the life cycle.158 
P. falciparum and P. knowlesi can infect all stages of red blood cells; 
parasitaemia (proportion of infected red cells) above 2% is associated with risk of 
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complications and death.158 P. vivax, P. ovale, and P. malariae invade red blood 
cells selectively (e.g. P. vivax only young erythrocytes), and parasitaemia is usually 
less than 1%.158 P. falciparum infection causes sequestration of infected red cells and 
their adherence to uninfected cells within the small vessels, leading to obstruction 
of blood flow, breakdown of the endothelial barrier, inflammation, and a complex 
cytokine reaction and host response.158 These events may result in tissue anoxia, 
multi-organ failure, and death.158 Other Plasmodium species are not sequestered 
substantially,158 and usually have a benign course. Recent studies have, however, 
reported from Indonesian Papua and India complicated P. vivax infections with 
mortality (0.8–3.9%).159–165 The pathogenesis of complicated P. vivax infection and 
that of P. knowlesi infection remain to be explored.
In P. falciparum malaria, the incubation period from transmission to 
symptoms is at least 7 days; in approximately 95% of cases symptoms occur within 4 
weeks. In P. knowlesi malaria, the incubation period is 9 to 12 days. In other species, 
symptoms may appear in 12 days to several months, in P. vivax and P. ovale even 
years after initial infection.158,166 The dominant symptoms of malaria in those who 
are non-immune are high fever with chills, often combined with headache and 
myalgias, sometimes with nausea, diarrhoea, or cough.167 Bouts of fever typically 
appear at regular intervals in P. vivax (48 h), P. ovale (48 h), and P. malariae 
(72 h) infections. In P. falciparum infection, fever exhibits no regular pattern. 
Clinically, infection caused by P. knowlesi is similar to that of P. falciparum.168–173 
Frequent infections in highly endemic areas result in development of partial 
immunity to clinical episodes of malaria.158 Asymptomatic, persistent  P.  falciparum 
parasitemia has been seen in immigrants even years after their leaving the endemic 
area.174–178 Degree of protective immunity is proportional to transmission intensity 
and requires repeated encounters with the parasite antigen158; it is therefore gradually 
lost after the individual leaves the endemic area. At highest risk for symptomatic 
and severe malaria are individuals without any immunity, like small children and 
non-immune visitors in malaria-endemic areas. Pregnant women179 and those who 
are immunosuppressed180 are also more prone to complications than are others.
2.2.3. MALARIA IN TRAVELLERS
RISK FOR MALARIA IN TRAVELLERS
The number of malaria cases in travellers from industrialized countries has been 
estimated to be 25 000/year; of these, approximately 10 000 are reported, and 
150 are fatal.181 The risk for acquiring malaria of non-immune travellers to malaria-
endemic countries has been calculated at 1 to 357/100 000, depending on country.61 
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Risk is highest in sub-Saharan Africa and Oceania, intermediate in southern Asia, 
and lowest in Central America, South America, and southeast Asia.61,79 Within sub-
Saharan Africa, risk is highest in western Africa.180,182 The extent of transmission 
varies widely and may be focal within countries and areas. Risk increases with length 
of stay; long-term travellers95 and VFR travellers72,74,79,100–102,114,116 are at highest risk. 
SEVERE MALARIA AND MORTALITY IN TRAVELLERS
The case fatality rate of imported Plasmodium falciparum malaria has ranged in 
most reports between 0.4% and 3.8%.65,183–190 Risk for severe malaria and death 
is related to several factors: delay between onset of symptoms and start of proper 
treatment,183,185,189,191–193 increasing age in the elderly,183,184,186,187,189,192,194–196 and failure 
to take antimalarial chemoprophylaxis.183–187,189,191,192,194 These studies suggest that 
even when chemoprophylaxis has failed to prevent malaria, it still has significantly 
reduced  risk of death. 
PREVENTION OF MALARIA IN TRAVELLERS
Risk for malaria can be reduced by preventing mosquito bites between dusk 
and dawn by means of clothing, insect repellents, and bed nets, and by 
use of appropriate chemoprophylaxis.180,182,197–200. The WHO201 and various 
national malaria chemoprophylaxis guidelines122,202–205 uniformly recommend 
continuous chemoprophylaxis for travellers to high-risk areas. In contrast, 
recommendations regarding areas with low-to-moderate malaria risk, or regions 
with P. vivax predominating, vary among national guidelines122,202–205 and vary by 
expert opinion206–209 depending on the risk-benefit analysis applied. Some authorities 
recommend continuous chemoprophylaxis, others seasonal chemoprophylaxis, no 
chemoprophylaxis, or standby emergency self-treatment.210 
The primary goal of malaria chemoprophylaxis is prevention of death, mainly 
caused by P. falciparum; the secondary goal is to prevent clinical malaria.199,210 The 
current recommended first-line drugs (atovaquone-proguanil, doxycycline, and 
mefloquine) are all considered over 90% effective in preventing clinical episodes 
of primary malaria infection.180,199 
Chloroquine is effective against P. falciparum only in Central America west 
of the Panama Canal, in the Caribbean, and in the Middle East. Mefloquine 
resistance has developed on the eastern and western borders of Thailand and in 
adjacent countries. Chloroquine-resistant P. vivax exists in Papua New Guinea 
and Indonesia.180,199 
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Atovaquone-proguanil, chloroquine, doxycycline, and mefloquine are active 
against the blood-stage parasites, but do not prevent relapsing infections caused 
by P. vivax and P. ovale hypnozoites. Primaquine is the only drug acting on liver 
hypnozoites and is used for completing the treatment of P. vivax and P. ovale 
malaria. Primaquine is also an alternative chemoprophylaxis for individuals not 
tolerating other drugs, provided that glucose-6-phosphate dehydrogenase (G6PD) 
deficiency has been excluded.180,182,197,199,210 
A randomized trial of adverse events related to prophylactic antimalarial 
drug regimens in non-immune travellers211 has showed atovaquone-proguanil 
and doxycycline to be better tolerated than are mefloquine and a combination of 
chloroquine and proguanil. A Cochrane review212 has shown the rate of adverse 
events to be equal for atovaquone-proguanil and doxycycline, slightly higher for 
mefloquine, and highest for a combination of chloroquine and proguanil. 
Studies of travellers’ knowledge, attitudes, and practices toward malaria 
prevention have shown gaps and need for improvement.40–45,213–215 While 
chemoprophylaxis clearly reduces the risk for acquiring malaria in non-immune 
persons, noncompliance with prophylactic medication has repeatedly been identified 
as a major factor raising risk for imported malaria.49,57,214,216–222 A study comparing 
self-reported compliance with antimalarial prophylaxis and blood concentrations 
of antimalarial drugs has shown that travellers significantly overestimate their own 
compliance.223 
DIAGNOSIS OF MALARIA 
Symptoms of malaria are non-specific and cannot be clinically distinguished from 
those of other febrile diseases.146,154 The gold standard of malaria diagnostics is 
light microscopy of Giemsa-stained thin and thick blood smears, but this  requires 
expertise and time. Polymerase chain reaction (PCR) tests are slightly more sensitive 
than microscopy and most useful for species identification and detection of mixed 
infections.224 PCR tests are not helpful for acute diagnostics, because results are 
usually not available as quickly as microscopy.122 Rapid diagnostic tests (RDTs) are 
increasingly used, especially outside specialized centres. RDTs have limitations  and, 
in addition to them, microscopy is still necessary to determine species and 
parasitemia percentages. Parasitemia is an essential parameter in P. falciparum 
and P. knowlesi malaria for evaluation of whether the patient has complicated 
malaria and also for monitoring the effect of treatment.167,224
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TREATMENT OF MALARIA 
WHO recommends oral artemisinin-based combination therapy (ACT) for 
uncomplicated P. falciparum malaria.225 P. vivax malaria can be treated with 
chloroquine, except in areas where P. vivax resistance to chloroquine has been 
documented (Papua New Guinea and Indonesia). Severe malaria is treated with 
injectable artesunate, followed by a complete course of an effective oral ACT as 
soon as the patient can take oral medications.225,226 
In non-endemic regions, treatment of malaria has varied between countries 
and centres; a retrospective analysis from 16 centres in 5 European countries, 
2003–2009, showed 18 combination regimens for malaria treatment.227 European 
experts published in 2012 recommendations for treatment of malaria in Europe,167 
ones which are in line with WHO guidelines. Oral ACTs are the recommended 
treatment of uncomplicated P. falciparum malaria, with atovaquone-proguanil as 
an alternative. If these first-line antimalarials are unavailable or cannot be used, 
a combination of quinine with either doxycycline or clindamycin, or mefloquine 
alone is the recommended second line treatment.167 In treatment of complicated 
P. falciparum malaria, intravenous artesunate has proved superior to intravenous 
quinine as regards overall survival, and it is simpler and safer to administer.228,229 
Artesunate is the first-line treatment in complicated malaria167,226,230,231; intravenous 
quinine combined with doxicyclin or clindamycin remains an alternative, if artesunate 
is unavailable or cannot be used.167 Patients treated with intravenous artesunate 
should be monitored for possible haemolysis for 4 weeks after treatment.167,232–235 
ACTs are effective also against P. vivax, P. ovale, P. malariae, and P. knowlesi, yet 
these species can be treated with chloroquine as well. After treatment of the acute 
infection, a course of primaquine is necessary in P. vivax and P. ovale malaria to 
prevent relapses from liver hypnozoites.167
2.2.4. IMPORTED MALARIA IN EUROPE
Earlier, malaria was endemic in Europe.236 The last indigenous case in Finland 
was reported in 1954,237 and in Italy in 1979.236 Reintroduction of the disease to 
the continent remains possible.236 The annual number of notified imported cases 
in European countries has been 10 000 to 13 000 (2–3/100 000 population) 
during more recent  decades, with France, the UK, Germany, and Italy accounting 
for more than 70% of all cases.238,239 In 2012, the WHO reported 5 500 cases of 
imported malaria in Europe,240 yet this figure may  be an underestimation.167 
Malaria is a notifiable disease in most European countries, but under-reporting 
may exist.167,236,238,241 Mortality in imported P. falciparum malaria in Europe has in 
various studies ranged from none to 3%.184,186,187,189,190,192 
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Imported malaria in Europe has been diagnosed among native Europeans, VFR 
travellers, foreign visitors, and immigrants arriving from malaria-endemic areas. 
Various studies have reported data on cases of imported malaria from European 
hospitals,242–244 cities,245,246 areas, 241,247 or countries188,248,249 (Table 5). Most of the 
imported cases in Europe have been P. falciparum infections acquired in sub-
Saharan Africa,4,65,99–102,188,192,241–249 similar to data in studies including non-European 
countries.68,74,79,147 A large proportion (28–65%) of malaria patients diagnosed in 
Europe have been VFR travellers.188,241–249  Regions for acquiring the infection reflect 
the geographic origin of the immigrant population in each European country and 
the risk for malaria in those regions. In most reports the majority of cases (52–98%) 
have been acquired in western Africa.188,241,243,244,247,248 An analysis of seven European 
studies in 2003 showed that 43% of imported malaria cases had been diagnosed in 
foreign-born residents, most of them VFR travellers, and their proportion seemed 
to be increasing.116 Many later studies have confirmed the increase in proportion of 
VFR travellers among malaria patients.188,243,246–248 In the UK, during 1987–2006, the 
number of reported malaria cases increased steadily, attributable to P. falciparum 
cases in VFR travellers to western Africa. During the same 20-year period, a decrease 
occurred in the number of P. vivax cases in travellers to southern Asia, most of 
them VFRs,248 which accords with other findings  of declining malaria incidence in 
travellers to India.250 In Italy, during 2000–2006, a constant decrease occurred in 
total incidence of imported malaria due to decrease in cases in travellers of Italian 
origin, while a concomitant increase was noted in the proportion of VFR travellers.188 
In contrast, in the Netherlands in 2000 to 2007, a decrease in incidence occurred 
both in tourists and in VFR travellers.249 
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3 AIMS OF THE STUDY 
This thesis investigated illness and injury in Finnish travellers, with a focus on 
infections. The main aim was to find tools for risk assessment, for pre-travel advice, 
and for post-travel examination of travellers. 
SPECIFIC AIMS WERE: 
1. to provide a comprehensive overview of illness and injury of Finnish  
travellers diagnosed while abroad, and to calculate the incidences in various 
geographic regions and countries (I)
2. to define the causes of fever in returning travellers and to improve clinical 
differential diagnostics (II)
3. to identify risk groups for imported malaria in Finland (III)
4. to analyze in detail the risk groups for imported malaria in Finland, and to 
explore whether Plasmodium falciparum infection can be contracted despite 
appropriate chemoprophylaxis (IV)
41
4 MATERIALS AND METHODS
4.1. STUDY I: ILLNESS AND INJURY OF FINNISH TRAVELLERS 
ABROAD 
4.1.1. MATERIAL
The study material comprised all Finnish travellers experiencing health problems 
abroad during 2010–2012, as recorded in the database of an assistance organization 
of insurance companies (SOS International). SOS covers approximately 95% of 
all Finnish cases abroad (77% of inpatient and 99.8% of outpatient cases) that 
are handled by assistance organizations. After a detailed analysis, these data were 
compared to the numbers of Finnish travellers in 2010 to 2012 as retrieved from 
the database of the Official Statistics of Finland (OSF).
4.1.2. DATA COLLECTION
Methods and definitions are described in more detail in the original article. 
Data from the assistance organization 
All data are registered and handled in a computerized database. The following 
information was available for the study: age, gender, time and country of illness 
or injury, inpatient or outpatient status, main diagnosis, repatriation, and death. A 
coordinating doctor is assigned to 86% of the inpatient cases, and to 1% of outpatient 
cases; such doctors coded diagnoses according to the International Statistical 
Classification of Diseases and Related Health Problems (ICD–10). Uncomplicated 
inpatient cases and 99% of outpatient cases are handled by non-medical assistance 
coordinators; they recorded the diagnoses provided by clinicians abroad as open 
text. A single coordinating doctor (H.S.) later encoded these diagnoses (45 475 cases) 
according to the ICD–10 classification. Diagnostic categories were those of ICD–10 
with the exception of infections, which were all separated from the organ-specific 
ICD–10 classification into a category of their own.
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Data on Finnish travellers 
The OSF data included annual numbers and average duration of at-least-overnight 
leisure and business trips abroad, and age-groups of travellers by region and country. 
Country-specific data were available for countries with >50 000 Finnish travellers/
year. OSF data had initially been retrieved by monthly sample-based computer-
assisted telephone interview surveys of the population of Finnish residents aged 15 
to 74; the upper age limit was extended to 84 years in 2012. The samples had been 
drawn by systematic sampling from the central population register. In 2010 and 
2011, the sample size had been 2 200 and, in 2012, 2 350 individuals per month.
Calculation of incidence
To be compatible with the OSF population, only adult cases aged 15 to 74 during 
2010–2011 and 15 to 84 during 2012 were included, and the geographic classification 
of OSF was applied for the calculation of incidence. The incidence of illness or injury 
was calculated per 100 000 travel days in various geographical regions and countries.
4.1.3. STATISTICAL ANALYSIS
The descriptive statistics were analyzed with Microsoft Excel 2010 and IBM 
SPSS statistics 19.0. Differences between groups were tested with the chi-square 
test, student’s t-test, and Mann-Whitney U-test, as appropriate. Risk factors for 
hospitalization were analyzed by logistic regression. Variables with p<0.2 in 
univariable analysis were subjected to a multivariable model. For variables lacking 
any reference category, deviation from average effect was used. 
Credible intervals (95%CI) for travel days of travellers with insurance, and thus 
95%CI for incidences, were estimated using Bayesian modeling with MCMC Gibbs 
sampling with informative priors. Following assumptions were used: proportion 
of travellers with insurance was lower (55–70%) for eastern and western Europe 
and higher (75–85%) for more distant destinations; trip durations were distributed 
similarly in 2010–2011 and in 2012. In numbers of travellers to each destination, 
sampling variation in the numbers of those answering was taken into account.
4.1.4. RESEARCH CLEARANCES
As this was a retrospective registry study based solely on a database without 
identification of any individual patient, no ethical approval was required. Instead, 
a research clearance was provided by SOS International.
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4.2. STUDY II: CAUSES OF FEVER IN TRAVELLERS RETURNING 
FROM MALARIA-ENDEMIC AREAS 
4.2.1. MATERIAL
The study subjects were travellers with fever admitted to the emergency room 
for internal and pulmonary medicine of Helsinki University Central Hospital 
(HUCH) between January 1, 2005, and March 31, 2009, after their trip to tropical 
or subtropical areas. Identification of these cases was retrospective, with a laboratory 
request for a malaria smear as a search tool; the first ten patients in each month 
were selected, and a total of 500 cases were collected. Adult patients (≥16 years) 
with fever (>37.5C) and a travel history to the tropics or subtropics within the 
previous year were included. The final analysis comprised 462 cases meeting these 
inclusion criteria.  
4.2.2. DATA COLLECTION
Methods and definitions are described in more detail in the original article. 
The following information was retrospectively collected from medical records: 
demographic data, detailed travel history, reason for travel, symptoms and their time 
of onset, chest x-ray and laboratory findings, antimicrobial treatment, diagnoses, and 
duration of hospitalization. The final etiological or clinical diagnosis of all patients, 
evaluated at least one year after discharge, was defined by H.S., who had access 
to all the results. 
4.2.3. STATISTICAL ANALYSIS
Chi-square tests, t-tests, and Mann-Whitney tests served to test for differences 
between groups. Binary and multinomial logistic regression models served to identify 
explanatory variables to the outcome variables. Variables found to have a p-value 
less than 0.2 were included in the multivariable models. To identify independent risk 
factors, forward and backward selection was with Akaike information criteria (AIC). 
For one variable (duration of trip), 72 values of the 462 were missing, and to take 
that into account in the model, we used multiple imputation with the assumption 
that the missingness process was missing at random (MAR). The analysis was 
carried out with SPSS 18.0.2 (SPSS Inc, Chicago, IL, USA). 
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4.2.4. RESEARCH CLEARANCES
The study protocol was approved by the Department of Internal Medicine of Helsinki 
University Central Hospital.
4.3. STUDY III: IMPORTED MALARIA IN FINLAND 1995–2008: 
AN OVERVIEW OF SURVEILLANCE, TRAVEL TRENDS, AND 
ANTIMALARIAL DRUG SALES
4.3.1. MATERIAL
The study material included nationwide population-based surveillance data on 
malaria cases reported to the National Infectious Disease Register (NIDR) of 
Finland during 1995–2008. This information was related to data on travelling 
and antimalarial drug sales. Numbers of travellers were retrieved from the Official 
Statistics of Finland (OSF) and the Association of Finnish Travel Agents (AFTA). OSF 
data included information on overnight leisure trips to malaria-endemic countries 
during 2000–2008. AFTA data included annual numbers of organized trips during 
1999–2007. The database of the Finnish Medicines Agency provided figures on 
antimalarial drug sales. 
4.3.2. DATA COLLECTED 
Methods and definitions are described in more detail in the original article. NIDR 
data included information on age, sex, nationality, date of diagnostic specimen, 
and country of infection. The National Population Information System provided 
additional data on country of birth and malaria-related deaths. 
4.3.3. STATISTICAL ANALYSIS
Descriptive and time series analyses were performed, as was linear regression 
for trend analysis. Data were analyzed using Stata software, version 10.0 (Stata 
Corporation, College Station, TX, USA).
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4.3.4. RESEARCH CLEARANCES
As this was a retrospective registry study based solely on a database, no ethical 
approval was required. Instead, research clearance was provided by the National 
Institute of Health and Welfare.
4.4. STUDY IV: IMPORTED MALARIA IN FINLAND 2003–2011: 
PROSPECTIVE NATIONWIDE DATA WITH RECHECKED 
BACKGROUND INFORMATION
4.4.1. MATERIAL
We examined in detail the background information on all cases of imported malaria 
confirmed and recorded by the reference laboratory of Finland (population 5.4 
million) between 2003 and 2011. We compared the cases with those reported to 
the National Infectious Disease Register. The information came from detailed 
questionnaires sent to the relevant clinicians upon diagnosis. H.S. sought missing 
data by use of telephone calls to the clinician or patient. 
4.4.2. DATA COLLECTION
Methods and definitions are described in detail in the original article. The following 
data were collected: demographic variables (sex, age, country of birth, nationality, 
recent and earlier countries of residence, date of immigration); detailed travel history 
(countries and areas visited, dates, reason for travel); pre-travel advice received; 
use of chemoprophylaxis; symptoms; date of onset, first contact with healthcare, 
presentation at hospital and diagnostic specimen; malaria species; diagnostic 
method; date of commencing treatment; medication used for treatment; time and 
place of diagnosis, treatment and hospitalization; complications and outcome. In 
all cases of P. falciparum malaria with self-reported compliant use of antimalarials, 
we rechecked the compliance.
4.4.3. STATISTICAL ANALYSIS
Differences between various groups were tested by the chi-square test, student’s 
t-test, or Mann-Whitney U-test, as appropriate. Statistical analyses were carried 
out with SPSS version 19.0 (Norusis; SPSS Inc., Chicago, IL, USA).
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MATERIALS AND METHODS
4.4.4. RESEARCH CLEARANCES
The study protocol was approved by and research clearance came from the 
Department of Internal Medicine of Helsinki University Central Hospital. The 
reference laboratory collected the information as part of its monitoring activity.
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5 RESULTS 
5.1. STUDY I: ILLNESS AND INJURY OF FINNISH  
TRAVELLERS ABROAD
5.1.1. PATIENT CHARACTERISTICS
The analysis included 50 710 cases: 42 371 (83.6%) outpatients, 8 339 (16.4%) 
inpatients. Median age was 45 years, and 45.1% were men. Inpatients were more 
often men (52.2% vs. 43.7%, p<0.001) than were outpatients, and were of higher 
median age (48 years, IQR 27–64, vs. 44 years, IQR 20–61; p<0.001). Most of the 
cases, 36 699 (72.4%), occurred in Europe and the eastern Mediterranean. The 
country with the highest number was Spain with 18 583 (36.6%) cases, of which 
13 435 (72.3%) were in the Canary Islands. 
5.2.2. DIAGNOSES
Infections represented the largest diagnostic category (59.9%), followed by injuries 
(14.0%), skin diseases (5.2%), musculoskeletal and soft tissue diseases (5.2%), 
diseases of the digestive tract (2.5%), and vascular diseases (2.1%). Infections 
and injuries were the largest diagnostic categories among both outpatients and 
inpatients. Proportions of infections and injuries of all diagnoses are presented 
in Figure 1 by geographic region. Skin-disease cases were most often treated as 
outpatients (99.0%), as were cases of musculoskeletal and connective tissue diseases 
(94.4%), whereas cases with vascular diseases were mostly treated as inpatients 
(65.9%). 
Acute gastroenteritis (11 543 cases) proved to be the most common single 
diagnosis and the most common type of infection (22.8% of all cases, 38.0% of 
infections, 20.9% of outpatients, 32.2% of inpatients). Respiratory tract infections 
(10 475 cases) were nearly as common (20.7% of all cases, 34.5% of infections, 23.0% 
of outpatients, 8.9% of inpatients). The other infection groups were: ear infections, 
3 843 (12.6%), dermatologic infections, 1 538 (5.1%), urogenital infections, 1 311 
(4.2%), eye infections, 955 (3.1%), systemic febrile infections, 673 (2.2%), and other 
infections, 55 (0.2%).
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RESULTS
Injuries comprised 5 567 (78.5%) traumas and 1 528 (21.5%) other injuries. Of 
traumas, 4 270 (76.7%) were superficial traumas, 952 (17.1%) fractures, and 287 
(5.2%) intracranial injuries. 
Travel itinerary remained unchanged in 48 842 (96.3%), an air ambulance was 
necessary for 113 (0.2%), and another re-arrangement of transport for 1 556 (3.1%) 
cases. The number of deaths was 199 (0.4%).
Figure 2  
Incidence of infections and injuries of adult travellers per 100 000 travel days by geographic region
Figure 1  
Percentages  of infections and injuries of all diagnoses by geographic region
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5.2.3. INCIDENCE OF ILLNESS AND INJURY
The overall incidence of illness and injury was high in Africa (97.9/100 000 travel 
days; BCI 53.1–145.5), southern Europe plus the eastern Mediterranean (92.3/100 
000 travel days; BCI 75.4–110.1), and Asia plus Oceania (65.0/100 000 travel days; 
BCI 41.5–87.9); the incidence was low in eastern plus western Europe (7.7/100 000 
travel days; BCI 6.3–9.4) and the Americas (7.6/100 000 travel days; BCI 4.7–11.5) 
(Table 6). Incidence of infections was high in Africa, southern Europe plus the 
eastern Mediterranean, and Asia plus Oceania; incidence of injuries was highest in 
southern Europe plus the eastern Mediterranean and Asia plus Oceania (Figure 2). 
Of the individual countries available for comparison, overall incidence was highest 
in Egypt, followed by Turkey and Thailand, mainly due to acute gastroenteritis.
The study revealed a significantly higher incidence of illness and injury in 
southern Europe than in eastern plus western Europe. In southern Europe plus 
the eastern Mediterranean, the incidence was 5-fold higher for injuries and 17-
fold higher for infections than in eastern plus western Europe. Comparison was 
possible between Portugal, Spain, Italy, Greece, and Turkey, and showed significant 
differences in incidences among them. In Italy and Portugal, overall incidence was 
similar to that of eastern plus western Europe. The incidence was highest in Turkey, 
attributable to acute gastroenteritis. Greece and Spain had the second and third 
highest incidences, mainly attributed to respiratory tract infections. 
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RESULTS
5.2. STUDY II: CAUSES OF FEVER IN TRAVELLERS RETURNING 
FROM MALARIA-ENDEMIC AREAS 
5.2.1. PATIENT CHARACTERISTICS
The study included 462 patients, of whom, 55% were men. Median duration of travel 
was 15 days (IQR 13–30). The regions visited most commonly were sub-Saharan 
Africa (42%), southeast Asia (28%), and central Asia plus the Indian subcontinent 
(20%).
5.2.2. DIAGNOSES
The most common main groups of diagnoses were: acute diarrhoeal disease (27%), 
systemic febrile illness (21%), and respiratory illness (15%). Campylobacter infection 
was the most common specific diagnosis (9%) and most common cause of acute 
diarrhoeal disease (32%). Malaria was diagnosed in 20 cases (4%). Blood culture 
was positive for bacteria in 21 cases (5% of the 428 tested): Salmonella species 5, 
Escherichia coli 3, Salmonella paratyphi 3, Salmonella typhi 2, Staphylococcus 
aureus 2, Burkholderia pseudomallei 1, Klebsiella pneumoniae 1, Pseudomonas 
aeruginosa 1, Shigella sonnei 1, Streptococcus pyogenes 1, Streptococcus viridans 
1. Nasal swabs for influenza A and B antigen were positive in 7 cases (15% of the 47 
tested); 111 cases fulfilled the criteria of influenza-like illness. HIV-antibody tests 
were run for 174 patients (38%) and proved positive in 5 (3% of those tested, 1% of 
all patients). A non-infectious disease was the cause of fever in 12 (3%); the reason 
remained unknown in 116 (25%) cases. More than one disease was diagnosed in 
45 (10%). The proportions of the diagnosis groups are presented in Figure 3, and 
the diagnoses in detail in Table 7.
A potentially life-threatening illness was diagnosed in 118 patients (26%); the 
strongest risk factors were baseline CRP >100 (OR 3.6; 95% CI 2.0–6.4) and 
platelet count <140 (OR 3.8; 95% CI 2.0–7.3). Nine patients (2%) were treated 
in high-dependency or intensive-care units. Mortality was 0.2%, one patient died 
of Pseudomonas septicemia. 
53
Acute diarrhoeal disease
Systemic febrile illness
Respiratory illness
Genitourinary diagnosis
Non-diarrhoeal gastrointestinal
diagnosis
Dermatologic diagnosis
Other specified noninfectious
diagnosis
No specific diagnosis
21.0
14.9
25.1
2.6
4.1
2.8
2.6
27.3
Acute diarrhoeal disease
Systemic febr e illness
Respiratory illness
Genitourinary diagnosis
Non-diarrhoeal gastroin estinal
diagnosis
Dermatologic diagnosis
Other specified oninfectious
diagnosis
No spe ific diagnosis
21.0
14.9
25.1
2.6
4.1
2.8
2.6
27.3
Figure 3 Percentages of groups of final diagnoses of 462 returned travellers with fever
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Table 7 Final diagnoses of 462 returned travellers with fever
 
Final diagnosis 1st diagnosisa
n
2nd and 3rd diagnosesb
n
ACUTE DIARRHOEAL DISEASE 126 (27.3%) 20 (40.8%)
Gastroenteritis NASc 59 2
Campylobacter infection 40 5
Salmonellosis 15 5
Shigellosis 5 0
Yersiniosis 4 1
Giardiasis 2 3
Clostridium difficile infection 1 2
Dieantamoeba fragilis infection 0 2
SYSTEMIC FEBRILE ILLNESS 95 (21.0%) 6 (12.2%)
Bacterial infections
Septicemiad 14 0
Unknown bacterial infection 8 0
Rickettsiosisd 6 0
Paratyphoid feverd 3 0
Typhoid feverd 2 0
Melioidosisd 2 0
Intra-abdominal abscessd 1 0
Leptospirosisd 1 0
Viral infections
Dengued 13 1
Acute viral infection 6 0
HIV infectiond 4 1
Epstein-Barr virus infection  4 2
Herpes simplex infection 3 1
Epidemic nephropathy 3 0
Viral meningitis 2 1
Cytomegalovirus infection 1 0
HHV-6 infection 1 0
Malaria  
P. falciparumd 16 0
P. vivax 2 0
P. ovale 1 0
Species unknown 1 0
Fungal infections
Pulmonary histoplasmosis 1 0
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Final diagnosis 1st diagnosisa
n
2nd and 3rd diagnosesb
n
RESPIRATORY ILLNESS 69 (14.9%) 9 (18.4%)
Upper respiratory tract infection 26 3
Pneumoniad 22 5
Influenza 8 0
Legionnaires’ diseased 1 0
Pulmonary tuberculosisd 1 0
Pneumocystis jirovecii pneumoniad 1 0
Atypical mycobacteria infection 0 1
NON-DIARRHOEAL 
GASTROINTESTINAL DIAGNOSIS
13 (2.8%) 3 (6.1%)
Viral hepatitis 2 1
Clonorchiasis 1 1
Other gastrointestinal diagnosesd,e 10 1
GENITOURINARY  DIAGNOSIS 19 (4.1%) 4 (8.2%)
Pyelonephritisd 16 0
Acute urinary tract infection 2 3
Generalized gonococcal infection 1 0
Spontanous abortion 0 1
DERMATOLOGIC DIAGNOSIS 12 (2.6%) 3 (6.1%)
Erysipelasd 8 0
Skin infection 3 2
Anaphylactic reactiond 1 0
Rash of unknown origin 0 1
OTHER SPECIFIED NON-INFECTIOUS 
DIAGNOSIS
12 (2.6%) 4 (8.2%)
Collagen disease 7 1
Sarcoidosis 2 0
Non-Hodgkin lymphomad 1 0
Subacute thyroiditis 1 0
Mefloquine intolerance 1 0
Eosinophilia 0 1
Rabies exposure 0 1
Tension neck 0 1
NO SPECIFIC DIAGNOSIS 116 (25.1%)
ALL (N) 462 49
adiagnosis regarded as the main cause of fever 
bother new independent diagnosis
ccausative agent remained unknown
ddisease potentially leading to death without specific or supportive treatment 
e 5 patients with potentially life-threatening illness: 3 pancreatitis, 1 cholangitis, 1 gastrointestinal bleeding 
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RESULTS
5.3. STUDY III: IMPORTED MALARIA IN FINLAND 1995–2008: 
AN OVERVIEW OF SURVEILLANCE, TRAVEL TRENDS, AND 
ANTIMALARIAL DRUG SALES
A total of 484 malaria cases (average annual incidence 0.7/100 000 population) 
were reported during the study period. The most common species diagnosed were 
Plasmodium falciparum (61%), and P. vivax (22%). Of these cases, 283 were 
Finnish-born and 201 foreign-born. Median age was 32 (range 0–80) years; 69% 
were men. Children comprised 15% of all cases; 72% of these were foreign-born, 28% 
Finnish-born. Infections were mostly acquired in Africa (76%). Among foreign-born 
cases, 89% of the malaria infections were acquired in the region of birth, mostly in 
Africa (106 cases). Three malaria-related deaths occurred during the study period. 
Travel to malaria-endemic areas increased during the study period, but no rise 
occurred in the number of imported malaria cases. A decreasing trend appeared 
in antimalarial drug sales. 
5.4. STUDY IV: IMPORTED MALARIA IN FINLAND 2003–2011: 
PROSPECTIVE NATIONWIDE DATA WITH RECHECKED 
BACKGROUND INFORMATION
Annual numbers of imported malaria cases from 1995 to 2011 are presented in 
Figure 4.  
During 2003–2011, a total of 265 malaria cases (average annual incidence rate 
0.5/100 000 population) were recorded by the reference laboratory; all of them 
were also reported to the NIDR. Plasmodium falciparum was the most common 
diagnosed species (72%) (Figure 5a). Most infections (81%) were contracted in 
0
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Figure 4 Annual number of imported malaria cases in Finland, 1995-2011
57
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Figure 5a Percentages of Plasmodium species 
of the 265 imported malaria cases in Finland, 
2003-2011
Figure 5b Geographic region for contracting 
malaria of the 265 imported cases in Finland, 
2003-2011, by percentage
Figure 6 Reason for travel of those importing 
the 265 malaria cases in Finland, 2003-2011, by 
percentage
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the Caribbean (8)
sub-Saharan Africa (Figure 5b). No malaria-related deaths were recorded during 
this study period. 
Median age was 31 years (range 1–71); 71% were men. Of all cases, 144 (54%) 
were born in malaria-endemic countries, and 229 (86%) were currently living 
in Finland or in another non-endemic region. Immigrants visiting friends and 
relatives (29%) and Finnish residents travelling as tourists (25%) constituted the 
largest groups of travellers (Figure 6). 
Pre-travel advice was received by 81% of those born in non-endemic regions, 
and 20% of those born in endemic regions. Regular use of appropriate malaria 
chemoprophylaxis was reported for 13 (5% of all cases), but for none of those 
born in an endemic area. Of those with P. falciparum, 4% reported regular 
use of appropriate chemoprophylaxis (atovaquone/proguanil or doxycycline or 
mefloquine for regions with chloroquine-resistant P. falciparum; atovaquone/
proguanil or doxycycline for regions with mefloquine-resistant P. falciparum). 
After individual rechecking, however, none of them was found to have been fully 
compliant.
Sub-Saharan Africa (214)
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81
7
7
3 3
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DISCUSSION
6 DISCUSSION 
In medicine and in research, travel medicine is a relatively new field. Escalating 
numbers of international travellers are expected to pose an increasing burden upon 
health care systems both in their destination countries during travel and in their 
home countries after return. Research data will aid in finding tools for preventive 
measures as well as for diagnostics and treatment of travel-related illnesses. 
6.1. STUDY I: ILLNESS AND INJURY OF FINNISH 
TRAVELLERS ABROAD
The perception of travellers’ health problems has relied on reports on relative 
morbidity, since the numbers of travellers to each region as denominator data to 
calculate the incidence have been unavailable.19 Study I was built on an exceptional 
situation in Finland, which has two large databases  available: one, that of a single 
assistance organization of insurance companies covering 95% of Finnish travellers 
using services of such organizations abroad, and the other of OSF, providing the 
numbers of Finnish travellers to various destinations. Combining data from these 
two sources made possible a nearly comprehensive nationwide analysis of relative 
morbidity for various diagnoses and made it possible to calculate incidences of 
illnesses and injuries during travel in individual geographical areas. 
The data include no information on those not contacting any insurance 
companies/assistance organizations while abroad (either making a claim directly 
to the insurance company later or not using their insurance) or on those without 
travel insurance. Because the study material covers 95% of all Finnish cases abroad 
handled by assistance organizations, the data can be considered to represent quite 
comprehensively travellers’ most serious health problems. One of the strengths of 
this study was the accuracy of diagnoses, since data came directly from clinicians 
treating the patient abroad.
As similarly suggested by prospective cohort studies,2,3,47,49–53,81,82 infections clearly 
outnumbered all other health problems during travel. This was the case not only in 
developing countries, but also in southern Europe and the eastern Mediterranean. 
The proportion of infections proved higher than in previous studies based on data 
from assistance organizations (60 % vs. 20–40%),85–87 probably because, instead 
of organ-specific categories, we included all infections in a category of their own. 
The most common infection and single diagnosis proved to be acute gastroenteritis 
(23%), consistent with earlier findings both on illness abroad2,3,15,33–37,47,49–53,81,82 
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and on returning travellers.2,4,74 Respiratory infections were nearly as common 
as gastroenteritis (21%). Prospective studies have reported between 2% and 26% 
of travellers to have respiratory infections during travel,2,3,47,49–53,81,82 and sentinel-
surveillance studies have shown between 8% and 11% of their patients with 
respiratory disease after travel.4,68,74,117 The latter report mainly cases in specialized 
tropical and travel medicine centres, while patients with post-travel respiratory 
symptoms probably seek help in primary care. 
As in other studies on health problems during travel,2,86 systemic febrile infections 
proved uncommon, and were markedly less frequent than in post-travel sentinel 
surveillance reports.4,68,70,74 The latter studies report malaria as the most frequent 
cause of systemic febrile illness in travellers.4,68,74,148 Our study, assumed to cover the 
most serious cases of illness, showed malaria to be rare during travel (8 cases, 3.5% of 
systemic febrile illnesses). Interestingly, the proportion of dengue (84 cases, 35.0% of 
systemic febrile illnesses) was higher than reported in returning travellers (10–15% of 
systemic febrile illnesses).68,74 During the study period, 85 imported cases of malaria 
and 190 of dengue were diagnosed in Finland251; thus, dengue symptoms seem to 
begin during travel more often than do those of malaria, consistent with dengue’s 
shorter incubation period. TD and respiratory infections have short incubation 
periods as well, which contributes to their high frequency during travel. As TD 
usually is a spontaneously resolving disease, and mild respiratory tract infections 
do not always lead to contact with health care providers, the proportion of those 
infections, although large in our study, probably still represents an underestimation 
of their real burden on travellers.
Many papers, such as GeoSentinel surveillance studies,68 have reported 
differences in relative morbidity between regions. In prospective cohort studies, 
the region with the highest relative morbidity has been dependent on the 
travel destinations of the study populations: e.g. either West Africa,3 the Indian 
subcontinent,2,52 or the Middle East and Latin America.53 One Swedish study49 
reported the highest attack rates of diarrhoea in travellers to northern Africa and the 
Indian subcontinent, followed by sub-Saharan Africa; a Swiss report50 in travellers 
to south Asia, followed by Latin America, southeast Asia, and sub-Saharan Africa. 
Our study gives incidences of illness and injury allowing comparisons between the 
various regions. The overall incidence proved high in Africa and, surprisingly, also 
in southern Europe plus the eastern Mediterranean, as well as Asia and Oceania. 
While the incidence of infections was high in Africa and Asia, it proved high also 
in southern Europe plus the eastern Mediterranean, 17-fold higher than in eastern 
plus western Europe. The profile of infections in southern Europe differed, however, 
from that in developing countries: instead of acute gastroenteritis, the incidence 
was highest for respiratory tract infections. 
60
DISCUSSION
In Spain, overall incidence was higher in the Canary Islands than on the 
mainland, which is partly explainable by the travellers’ higher median age and longer 
trip duration. Within southern Europe, we found between countries significant 
differences not solely explained by trip duration or traveller age. Although a low 
risk for gastroenteritis has been reported in southern Europe,80 our study indicated 
elevated incidences in Greece and Spain. As also shown by others,4,82 our study 
revealed that travelling within Europe is not without risk. This study showed that 
pre-travel counselling is needed also for travel to southern Europe.
These results provide tools for destination-specific risk assessment, travel 
counselling, and post-travel evaluation. This study shows that pre-travel advice 
should focus not only on safe food and drink abroad, but also on good hand hygiene 
for prevention of gastrointestinal and respiratory infections. Improved means for 
prevention of gastrointestinal and respiratory infections in travellers are needed.  
6.2. STUDY II: CAUSES OF FEVER IN TRAVELLERS RETURNING 
FROM MALARIA-ENDEMIC AREAS
Study II was designed to find the causes of travel-related fever after a journey; 
the data were expected to provide tools for diagnostics and treatment. We used 
the disease classification of GeoSentinel.147 Our data represented patients in an 
emergency department of a main tertiary referral hospital, whereas GeoSentinel 
sites are centres of tropical and travel medicine. We found equal proportions of 
respiratory illnesses (15% vs. 14%), but more acute diarrhoeal diseases (27% vs. 
15%) and less systemic febrile illness (21% vs. 35%), suggesting that the GeoSentinel 
patient material147 has been more selected. 
Malaria has been reported as the most frequent cause of fever without localizing 
symptoms in returning travellers in other hospital-based26,27,94,98–102 and sentinel-
surveillance4,68,74,147 studies. Although the most commonly visited region in our 
study population was sub-Saharan Africa, similar to most other studies (42% vs. 
34–86%),4,27,68,98–102,147 we found malaria in only 4%, as compared with 21 to 75% in 
the other studies,26,27,94,98–102,147 suggesting their more selected material. 
We took blood cultures from 93% of patients, and septicemia proved as common 
as malaria (5% vs. 4%). In most similar studies, a septicemia diagnosis has not 
been sought.27,94,100,102,147 In those reporting it, the rate of septicaemia has ranged 
from 0.1 to 2%, yet blood cultures had not been run routinely from all of those 
patients.26,98,99,101 In one Italian study,99 blood culture was done for 56%, and found 
positive in 10% of them. 
In one GeoSentinel series in which 91% of patients had fever, an acute and 
potentially life-threatening tropical disease was diagnosed in 4.4%5; in our study, 
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5% of returned travellers with fever fulfilled the same criteria. Another definition: 
that of a disease potentially leading to death if left without specific or supportive 
treatment was met by 26% of our patients, suggesting that the referral criteria had 
been correct. 
Nasopharyngeal swabs for influenza A and B antigen proved positive in 15% 
of those we tested; yet swabs were taken from only 42% of those retrospectively 
evaluated to have fulfilled the criteria of an influenza-like illness. This supports the 
findings of earlier studies based on serology142,150 suggesting influenza in travellers 
to be under-diagnosed. Influenza is the most common vaccine-preventable disease 
of travellers142 and should be considered in the differential diagnostics of febrile 
travellers also outside the epidemic season of the northern hemisphere.   
A new HIV diagnosis was established in 3% of the 174 tested, 1% of all our 
patients. Other studies have reported newly diagnosed HIV infections in 0.3 to 1.5% 
of febrile returned travellers, yet not all patients had been tested.26,98–102 A GeoSentinel 
study reported sexually transmitted disease (STD) in 0.9% of ill travellers; HIV 
was diagnosed in 2% of all those presenting after travel.252 HIV infection has been 
the diagnosis for 4% of returned travellers presenting with mucocutaneous signs 
suggesting a STD,253 3% of those with fever and exanthema,254 and 7% of those with 
infectious mononucleosis-like syndromes.255 In these studies, too, patients had not 
been systematically tested for HIV. The Centers for Disease Control and Prevention 
in the USA (CDC) recommends offering routine HIV-testing for everyone in contact 
with health care in populations where the prevalence of HIV is >0.1%.256 Therefore, 
it seems justified to recommend HIV tests for all travellers returning ill.
The cause of fever remained unknown in 25% of cases, similar to other 
studies’ findings (5–24%),26,27,94,100–102,147 all of them with a benign course. Mortality 
corresponded to that in other reports (0.2% vs. 0.2–0.5%).94,101,147 Non-infectious 
diseases were the cause of fever in 3% of our patients, compared to 0 to 5% in 
other studies.26,27,98–102  One patient in ten had more than one separate diagnosis, 
similar to figures in other reports (10–16%),98,99,101 showing  the importance of careful 
diagnostics in returning travellers with fever.
6.3. STUDIES III AND IV: MALARIA
All malaria cases diagnosed in Finland are imported; autochthonous malaria has 
not appeared in Finland since the 1950s.237 Although under-reporting of imported 
malaria cases occurs in Europe,238 it seems that no under-reporting occurs  in 
Finland: the same individual cases were identified annually in the notifications to 
the National Infectious Disease Register and in the data of the reference laboratory 
both in Study III and in Study IV. 
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6.3.1. STUDY III: IMPORTED MALARIA IN FINLAND 1995–2008 AN OVERVIEW OF 
SURVEILLANCE, TRAVEL TRENDS, AND ANTIMALARIAL DRUG SALES
Study III compared malaria notification data, travel statistics, and malaria 
chemoprophylaxis drug sales during 1995–2008. Travelling to malaria-endemic 
areas increased during the study period, yet no increase occurred in the number of 
imported malaria cases except for a peak in the last quarter of 2008 due to a cluster 
of travellers to the Gambia.257 Asia is the tropical area most favoured by Finnish 
travellers,6 yet the majority of our malaria cases were acquired in sub-Saharan Africa, 
correlating with the highest incidence of malaria in this region.155 The increase in 
number of trips was mostly to areas with limited risk, which may in part explain 
why the number of malaria cases remained stable. On the other hand, it may also 
reflect a decreasing malaria risk for travellers in endemic areas as is reported from 
Latin America,258 West Africa,259 India,250 and southeast Asia.260 
Sales of drugs for malaria chemoprophylaxis decreased after 1997, and then 
began to increase slowly from 2005 onward, coinciding with atovaquone/proguanil 
coming onto the market. Notably, although included in the Finnish guidelines for 
malaria chemoprophylaxis, doxycyclin was not included in our analysis, since it 
is used mainly for other indications. Data on drug sales may thus be misleading, 
and the decrease observed in the sales of other drugs may be due to a respective 
increase in the doxycycline sales. A decreasing trend for antimalarial drug sales 
can be explained also by other factors, such as travellers’ under-estimation of risk 
for malaria,41 their fearing adverse drug reactions 215 or their purchasing the drugs 
only at their destination.208 Moreover, compliance with antimalarials is reportedly 
low. 49,57,214,216,217,219–222 Thus antimalarial drug sales alone fails to allow estimation 
of chemoprophylaxis use.
Approximately 40% of the malaria cases occurred among foreign-born 
individuals; 90% of them were VFR travellers, most frequently those born in Africa 
— the most common region for contracting the disease. These data are in line with 
other European findings.188,241–249 Children constituted 15% of all and more than 
one-quarter of foreign-born cases, similar to others’ figures.106 Children reportedly 
comprise from 11 to 23% of all imported cases of malaria, with the majority of their 
infections being acquired in sub-Saharan Africa, and with a larger proportion of 
children than adults as being VFR (50–84%).106 VFR children more often have 
symptomatic malaria and have higher parasite density than do recently arrived 
immigrant children, who have some partial immunity.261 Children are at  higher 
risk of developing complicated disease: 5 to 10% of children with imported malaria 
have had severe cases.262 Our study confirmed that immigrants visiting friends and 
relatives in their country of origin, especially children of immigrant families, are at 
high risk  for malaria. More effort should focus on disseminating pre-travel advice 
to this risk group.
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6.3.2. STUDY IV: IMPORTED MALARIA IN FINLAND 2003–2011 : PROSPECTIVE 
NATIONWIDE DATA WITH RECHECKED BACKGROUND INFORMATION
Study IV analyzed in detail background information on imported malaria cases in 
Finland from 2003 to 2011. Distribution of age, gender, malaria species, duration 
of travel, geographic regions, and risk groups were in line with other European 
figures.188,241–249,263 No malaria-related deaths occurred in Finland during this period. 
Immigrants constituted 117 (44%) of all cases: 29% were VFR travellers, and 
15% recently arrived immigrants. Our study confirmed that VFR travellers are a risk 
group: they received less pre-travel advice than the Finnish-born cases, and none 
took appropriate chemoprophylaxis regularly. The proportion of VFR travellers has 
been large also in several other European reports.188,241–249,263 Adult VFR travellers 
have been less likely to seek pre-travel advice and use effective malaria prophylaxis 
than are non-VFR travellers,115 and VFR children use chemoprophylaxis even less 
frequently.262 Lack of malaria prophylaxis has been suggested to be due to a lack of 
knowledge of malaria transmission and prevention,214,264,265 and erroneous trust in 
livelong immunity.113,116,199 VFR travellers may be more heavily exposed to malaria 
than others since they frequently visit rural areas and often during the rainy season.116 
Partial immunity developed while growing up in highly endemic areas wanes with 
time and no longer protects the adults from clinical malaria, yet it may protect from 
fatal complications. Consistent with other reports,174,189–191 in our study those born in 
malaria-endemic regions had fewer complications than did those born in Finland 
or other non-endemic countries. The non-immune children of immigrant families 
are at greatest risk for symptomatic and severe malaria.79,116,266 Pre-travel advice 
should thus be actively offered to immigrants during every  contact they have with 
health-care services, whenever plans to travel to malaria-endemic country emerge. 
Finnish travellers with malaria proved not to have taken appropriate 
chemoprophylaxis, even though having received pre-travel advice. Despite the 
fact that national guidelines are easily available,205 in five cases the physician had 
incorrectly advised against chemoprophylaxis and in 19 cases the drug prescribed 
was inappropriate. This highlights the importance of continuous training of health-
care professionals. In nine cases, the traveller had bought inappropriate over-the-
counter drugs at the destination. Pre-travel advice should emphasize the dangers 
of buying drugs in endemic countries, as such may not only provide inappropriate 
chemoprophylaxis, but may also be counterfeit drugs.267
No doctors’ delay occurred from presentation at hospital to diagnosis or the start 
of anti-malarial treatment; it thus seems that Finnish doctors working in hospitals 
are familiar with guidelines on diagnostics and treatment of malaria268,269 and 
suspect malaria in febrile returning travellers. Most malaria patients were treated 
as inpatients, in accordance with European guidelines.167 The median length of 
hospital stay was five days, similar to that in other European surveys.243,246,263 Length 
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of hospitalization decreased  during the study period, reflecting a change in treatment 
guidelines: since 2010 uncomplicated malaria has been treated with ACT (oral 
artemether/lumefantrine) instead of quinine plus doxycycline. Subsequently, in 
2010, the hospital stay decreased to four days, and, in 2011, further to three days.
Cases of P. falciparum malaria have occurred despite reported appropriate 
chemoprophylaxis188,241,245–247,263; this information has been recorded, however, 
without reconfirmation of compliance. Adherence to chemoprophylaxis is difficult to 
assess in data based on questionnaires only,188,241,248,263 with self-reported adherence 
higher than it is in actuality.223,270 The question remaining is whether significant 
clinical resistance exists to drugs currently used for chemoprophylaxis. In our 
study, 4% of patients with P. falciparum malaria reported taking appropriate 
chemoprophylaxis regularly. When this was rechecked, all of them, however, 
admitted having been non-compliant. This study demonstrates that information 
on compliance may be unreliable, and such information should undergo a recheck 
in all cases of malaria. These results suggest that mefloquine, atovaquone/proguanil, 
and doxycycline are effective as chemoprophylaxis against P. falciparum malaria, 
when taken conscientiously.
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7 CONCLUSIONS AND FUTURE PROSPECTS
Means for prevention of gastrointestinal and respiratory infections in travellers 
call for development; the data show a need for vaccines against enteric pathogens. 
Immigrants visiting friends and relatives in their country of origin, especially 
children of immigrant families, are at high risk for contracting malaria; more effort 
should focus upon dissemination of pre-travel advice to this group. Atovaquone/
proguanil, doxycycline, and mefloquine seem effective as chemoprophylaxis against 
P. falciparum malaria, but travellers should take these conscientiously. 
Although gastrointestinal and respiratory infections proved the most common 
health problems, malaria and other potentially life-threatening illnesses should 
continuously be emphasized because of their serious nature if left undiagnosed and 
untreated. In a tertiary hospital, fever without localizing symptoms in a traveller 
returning from malaria-endemic area should require a diagnostic protocol that, in 
addition to malaria smears, includes blood cultures, an HIV test, and an influenza 
rapid diagnostic test.  
The database of an assistance organization of insurance companies proved a 
unique and valuable source of information on illness and injury diagnosed during 
travel. More detailed data are necessary, however, as to reason for and length 
of travel, travel itinerary, reason for injury, length of hospital treatment, and 
transportation of those fallen ill or injured abroad. This would prove useful both 
for development of assistance services and for planning of preventive strategies. The 
malaria surveillance system in Finland needs improvement: important background 
information resides in an additional register, but is missing from the main register 
and should be linked to it. 
With expanding travel and migration, health professionals will increasingly 
be faced with health problems related to travel. Research and resources in this 
field will aid in development of prevention, diagnostics, and treatment. European 
and international cooperation is essential in surveillance of, research into, and 
establishment of guidelines on illnesses and injuries of migrants and travellers. 
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